S1PR1 activation by sphingosine 1-phosphate is essential for neuronal events, and its dysregulation may contribute to the pathogenesis of Alzheimer’s disease.6,7 A promising target for treating a variety of human diseases, the availability of high-performing S1PR1 antibodies would facilitate S1PR1 research and help uncover therapeutic strategies.3 The gene discussed is S1PR1; the disease is early-onset autosomal dominant Alzheimer disease.